CheckMyRecalls

10,013 recalls · updated 20 Nov 2026

Cardinal Health Inc. recalls RECOMBINATE and 1 more

Read the official FDA notice

Published
13 Aug 2025
Units affected
3 products
Agency
FDA
Country
United States

The hazard

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01

Xolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South San Francisco, CA 94080, NDC 50242-214-55

Xolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech, Inc, South San Francisco, CA 9408, NDC: 50242-215-55.

Brand / company
Cardinal Health Inc.
Codes / lots
Lot: TRB23802AC, Expires: 03/18/2026; TRA22804AA, Expires: 10/18/2025 | Lot: 3630004, Expires: 10/31/2025. | Lot: 3617756, Expires: 12/31/2025.
Distribution
Nationwide Within the U.S.
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 13 Aug 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.